Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hiroaki Mitsuya

The High Genetic Barrier of EFdA/MK-8591 Stems From Strong Interactions With the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase

Cell Chemical Biology

Clinical Biochemistry

Drug Discovery

2018

English

C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, Including Darunavir

English

CMCdG, a Novel Nucleoside Analog, Exerts Potent Activity Against Wild-Type and Entecavir-Resistant HBV With Favorable Safety Feature

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2019

English

3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2017

English

Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI)(GRL-001-15 and GRL-003-15) With the Flap of Protease Are Critical for Their Potent Activity Against Wild-Type and Multi-Pi-Resistant HIV-1 Variants

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2019

English

Novel Protease Inhibitors Containing C-5-Modified Bis-THF and Aminobenzothiazole as P2 and P2′ Ligands That Exert Potent Antiviral Activity Against Highly Multidrug-Resistant HIV-1 With High Genetic Barrier Against the Emergence of Drug Resistance.

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2019

English

Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2019

English

Probing the Molecular Mechanism of Action of the HIV-1 Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine (EFdA) Using Pre-Steady-State Kinetics

English

Potent HIV‐1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein‐ligand X‐ray Structural Studies

English

Successful Treatment of Cisplatin Overdose With Plasma Exchange

Case Reports in Medicine

Medicine

2010

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hiroaki Mitsuya

The High Genetic Barrier of EFdA/MK-8591 Stems From Strong Interactions With the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase

C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, Including Darunavir

CMCdG, a Novel Nucleoside Analog, Exerts Potent Activity Against Wild-Type and Entecavir-Resistant HBV With Favorable Safety Feature

3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H

Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI)(GRL-001-15 and GRL-003-15) With the Flap of Protease Are Critical for Their Potent Activity Against Wild-Type and Multi-Pi-Resistant HIV-1 Variants

Novel Protease Inhibitors Containing C-5-Modified Bis-THF and Aminobenzothiazole as P2 and P2′ Ligands That Exert Potent Antiviral Activity Against Highly Multidrug-Resistant HIV-1 With High Genetic Barrier Against the Emergence of Drug Resistance.

Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications

Probing the Molecular Mechanism of Action of the HIV-1 Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine (EFdA) Using Pre-Steady-State Kinetics

Potent HIV‐1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein‐ligand X‐ray Structural Studies

Successful Treatment of Cisplatin Overdose With Plasma Exchange